Substituted quinolineins used as improved inhibitors of NF-κB (NIK)-inducing kinase
MA71481B1Active Publication Date: 2026-06-30NIKAIA PHARMACEUTICALS +4
Patent Information
- Application Number
- MA71481
- Authority / Receiving Office
- MA · MA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-10-25
- Filing Date
- 2022-10-25
- Publication Date
- 2026-06-30
- Estimated Expiration
- 2042-10-25
Abstract
<pre>The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as NF-κB (NIK)-inducing kinase inhibitors and, in particular, can induce the intracellular degradation of NIK, making these compounds highly advantageous for use in therapy, including for the treatment or prevention of cancer, inflammatory diseases, and autoimmune diseases.< / pre>
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
4-anilino-quinoline compounds as Anti-cancer agents
WO2018007648A1
New substituted azaindoline derivatives as NIK inhibitors
WO2019008011A1
Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia
WO2019134969A1
Heterocyclic compounds and methods of use
WO2020012357A1
TOPOISOMERASE II-alpha INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME
WO2020205991A1